Cancer Biology

癌症生物学

基本信息

批准号：
8369385
负责人：
MICHELE CARBONE
金额：
$ 2.33万
依托单位：
UNIVERSITY OF HAWAII AT MANOA
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-07-01 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8369385
关键词：
Area Basic Cancer Research Basic Science Biochemical Biochemistry Biological Assay Biological Factors Biology Biophysics Cancer Biology Cancer Center Cancer Center Support Grant Cancer Etiology Cellular biology Chemicals Chemoprevention Clinic Clinical Collaborations Development Diagnosis Diagnostic Discipline Early Diagnosis Faculty Focus Groups Fostering Foundations Funding Genetic Goals Hawaii Immunobiology Incubators Inflammation Intervention Investigation Lead Malignant Neoplasms Malignant neoplasm of liver Medical center Membrane Mesothelioma Modality Molecular Molecular Biology Molecular Genetics Movement Operative Surgical Procedures Pathology Pathway interactions Pharmaceutical Preparations Pharmacy facility Prevention Preventive Primary carcinoma of the liver cells Process Publications Recruitment Activity Research Research Personnel Research Project Grants Resources Rest Scientist Signal Pathway Signal Transduction Synthesis Chemistry Therapeutic Translating Translational Research Translations United States National Institutes of Health Universities Work base cancer epidemiology cancer initiation cancer prevention cancer therapy clinical application college drug discovery innovation insight medical schools member new therapeutic target novel novel diagnostics novel therapeutics programs scientific organization small molecule tool tumor initiation virology

项目摘要

Basic research in cancer biology is paramount to unraveling and understanding the mechanisms of cancer development and progression. Novel insights obtained from basic research investigations are critical for generating new ideas and strategies for cancer prevention, diagnosis and therapy. Members of the Cancer Biology Program (CB) investigate the fundamental cellular, molecular, genetic, biochemical, and immunological mechanisms of cancer biology and develop molecular tools and experimental therapeutics that modulate them. The program has 31 actively participating members from the University of Hawaii's Cancer Center, School of Medicine, and College of Pharmacy as well as the Queen's Medical Center. Of these 25 have joined since the previous review. CB members currently receive a combined $5.63M annually in direct funding, including $3.76M from the NCI and $1.79M in other NIH support. Over the past five years, they have authored a total of 193 cancer-related publications, of which 21% originated from intraprogrammatic, 12% from inter-programmatic, and 5% from inter/intra-programmatic collaborations. The primary goal of the CB is to foster translational research through multi-disciplinary collaborations where investigations of the cellular and molecular mechanisms of cancer development and progression lead to the identification of novel therapeutic targets and potential strategies for cancer prevention, early detection, diagnosis, drug discovery and treatment. The major goals of the program are (1) to generate novel mechanistic insight into the processes that drive tumor initiation, progression, and invasion (Cancer Mechanisms); (2) to target these mechanisms with new small molecules and natural products using cellular and biochemical assays (Drug Discovery); (3) to translate these results into more effective preventive, early detection, and therapeutic modalities (Diagnostics & Intervention). Members of the program have complementary expertise in cell and molecular biology (signal transduction, membrane biophysics, immunobiology and inflammation, and genetics), virology, chemical biology (biochemistry, synthetic chemistry, natural products), pathology and surgery. In addition, the program also includes focus groups dedicated to the investigation of specific cancers. These focus groups provide a framework to translate novel research findings into the development of targeted clinical interventions or innovative diagnostic approaches in these cancers.

癌症生物学的基础研究对于阐明和理解癌症发展和进展的机制至关重要。从基础研究研究中获得的新见解对于为预防癌症，诊断和治疗的新思想和策略至关重要。癌症生物学计划（CB）的成员研究了癌症生物学的基本细胞，分子，遗传，生化和免疫机制，并开发了调节它们的分子工具和实验性治疗剂。该计划拥有夏威夷大学癌症中心，医学院和药学院以及女王医学中心的31名积极参与的成员。自上一篇评论以来，这25个加入了。 CB成员目前每年获得563万美元的直接资金，其中包括NCI的376万美元和179万美元的其他NIH支持。在过去的五年中，他们总共撰写了193个与癌症相关的出版物，其中21％源自术中，12％来自程序间截图，而5％来自间/跨编程内的合作。 CB的主要目的是通过多学科的合作来促进翻译研究，其中对癌症发展和进展的细胞和分子机制进行研究，导致鉴定出新的治疗靶标，以及预防癌症预防，早期发现，诊断，药物发现和治疗的潜在策略。该计划的主要目标是（1）对驱动肿瘤起始，进展和侵袭的过程产生新的机械洞察力（癌症机制）；（2）使用细胞和生化测定（药物发现）用新的小分子和天然产物来靶向这些机制；（3）将这些结果转化为更有效的预防，早期检测和治疗方式（诊断和干预）。该计划的成员在细胞和分子生物学（信号转导，膜生物物理学，免疫生物学和炎症以及遗传学），病毒学，化学生物学（生物化学，合成化学，天然产物），病理学和手术方面具有互补的专业知识。此外，该计划还包括致力于调查特定癌症的焦点小组。这些焦点小组提供了一个框架，将新颖的研究结果转化为这些癌症中有针对性的临床干预措施或创新诊断方法的发展。